Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDM4E | B2RXH2 | 5/20 | 0.40 |
| ▸ | ALDH1A1 | P00352 | 5/20 | 0.40 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.37 |
| ▸ | MEN1 | O00255 | 2/20 | 0.37 |
| ▸ | NPC1 | O15118 | 2/20 | 0.36 |
| ▸ | RAB9A | P51151 | 2/20 | 0.36 |
| ▸ | LMNA | P02545 | 1/20 | 0.36 |
| ▸ | RXFP1 | Q9HBX9 | 1/20 | 0.36 |
| ▸ | L3MBTL1 | Q9Y468 | 2/20 | 0.36 |
| ▸ | CDC7 | O00311 | 1/20 | 0.35 |
| ▸ | RECQL | P46063 | 1/20 | 0.35 |
| ▸ | HTT | P42858 | 1/20 | 0.35 |
| ▸ | PDE4B | Q07343 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL14038312 | 0.85 | NPC1 (0.32) | NPC1RAB9A | |
| SCHEMBL4904456 | 0.84 | KDM4E (0.37) | KDM4EALDH1A1KMT2AMEN1NPC1 | |
| SCHEMBL14034638 | 0.79 | KDM5A (0.32) | NPC1RAB9A | |
| SCHEMBL14088339 | 0.78 | MAPK1 (0.52) | KDM4EALDH1A1KMT2AMEN1LMNA | |
| SCHEMBL14007538 | 0.77 | NPC1 (0.33) | NPC1RAB9A | |
| SCHEMBL4900019 | 0.75 | ALOX15 (0.39) | KDM4EALDH1A1RXFP1L3MBTL1HTT | |
| SCHEMBL4575054 | 0.72 | KDM4E (0.45) | KDM4EALDH1A1KMT2ALMNARECQL | |
| SCHEMBL14006495 | 0.70 | ALDH1A1 (0.40) | KDM4EALDH1A1NPC1LMNARECQL | |
| SCHEMBL4909426 | 0.67 | ALDH1A1 (0.40) | KDM4EALDH1A1KMT2AMEN1LMNA | |
| SCHEMBL4574836 | 0.66 | LMNA (0.41) | KDM4EALDH1A1LMNARECQLHTT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2008144500-A2 | 1-METHYL-BENZO[1,2,4]THIADIAZINE, 1-OXIDE DERIVATIVES | ANADYS PHARMACEUTICALS, INC. (US) | 2008-11-27 | — | — | WO | disclosed |
| WO-2008144500-A2 | 1-METHYL-BENZO[1,2,4]THIADIAZINE, 1-OXIDE DERIVATIVES | ANADYS PHARMACEUTICALS, INC. (US) | 2008-11-27 | — | — | WO | disclosed |
| US-20080292588-A1 | 1-METHYL-BENZO[1,2,4]THIADIAZINE 1-OXIDE DERIVATIVES | ANADYS PHARMACEUTICALS, INC. (US) | 2008-11-27 | — | — | US | disclosed |
| US-20080292588-A1 | 1-METHYL-BENZO[1,2,4]THIADIAZINE 1-OXIDE DERIVATIVES | ANADYS PHARMACEUTICALS, INC. (US) | 2008-11-27 | — | — | US | disclosed |
| US-20080292588-A1 | 1-METHYL-BENZO[1,2,4]THIADIAZINE 1-OXIDE DERIVATIVES | ANADYS PHARMACEUTICALS, INC. (US) | 2008-11-27 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080292588-A1 | 1-METHYL-BENZO[1,2,4]THIADIAZINE 1-OXIDE DERIVATIVES | CYP1B1, CYP2E1, DAZAP1 | KDM4E 668/4885ALDH1A1 143/4885KMT2A 1229/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.